A Cleveland Clinic anesthesiologist turned her Parkinson’s diagnosis into a research and racing mission — joining a cycling trial researchers say may slow disease.

UH researchers at the Harrington Discovery Institute identified Golgi proteins that help route growth-factor receptors to the cell surface, suggesting a new target for resistant tumors. The work is promising but preclinical.

Interim data show a single infusion of a PCSK9 base editor sharply lowered LDL in an early trial, while Cleveland researchers link low nitric oxide to altered gene splicing in Alzheimer’s. Clinicians warned that supplements aren’t regulated like drugs and can carry risks.